Technology Platform

Technology platform

Botulinum neurotoxin domains as tools for engineering novel molecules

 

Syntaxin’s TSI are novel recombinant proteins designed to exploit the unique pharmacology inherent in bacterial botulinum neurotoxins

 

Patient Focus

Patient focus

New medicines for debilitating and life threatening diseases

 

Syntaxin is a leader in botulinum toxin biology and applies its expertise to the identification of new therapeutic opportunities

 

Latest News

08 May 2013

Syntaxin Hosting Biological Safety: Management and Practice Open Training Course, 11-12 July 2013

Syntaxin Hosting Biological Safety: Management and Practice Open Train...

29 March 2012

Melanie Lee, CEO of Syntaxin, joins the Board of Lundbeck

Oxford (UK), 29 March 2012 - Syntaxin, a biotechnology company special...